secwatch.observer — SEC 8-K summary
======================================

Issuer:     Endo International plc (—)
CIK:        0001593034
Form:       8-K
Filed at:   2022-12-06T23:59:59+00:00
Accession:  0001193125-22-299492
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 2.06, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Endo ceases QWO production & sales due to bruising concerns; expects $235-250M Q4 restructuring charges
--------------------------------------------------------------------------------

- Ceasing Endo Aesthetics' QWO (cellulite treatment) due to market concerns about bruising and skin discoloration.
- Annualized pre-tax cash savings of $50-60M; workforce reduction of ~90 positions.
- Q4 2022 pre-tax restructuring charges of $235-250M, mainly non-cash asset impairment of $220-230M.
- Seeking bankruptcy court approval for the decision; QWO remains FDA-approved but not commercially viable.
- APHRODITE study showed modest bruising reduction but not enough to alleviate market concerns.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593034/000119312522299492/0001193125-22-299492-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593034/000119312522299492/d410746d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-299492

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer